Business Wire

Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure

Del

Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced plans to conduct two outcome trials investigating the diabetes medicine Jardiance® (empagliflozin) for the treatment of people with chronic heart failure. The trials are targeted to begin within the next 12 months and are planned to enrol people with chronic heart failure both with and without type 2 diabetes (T2D).

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160419005757/en/

Jardiance® was the first diabetes treatment to demonstrate a reduction in the risk of cardiovascular (CV) death in a dedicated CV outcomes trial. This was demonstrated on top of standard of care (including glucose-lowering agents and CV drugs) in people with T2D at high risk of CV events. In addition to reducing CV death by 38 percent, the EMPA-REG OUTCOME® trial also showed that Jardiance® reduced the risk of hospitalisation for heart failure in people with T2D at high risk of CV events by 35 percent. These results led to the planned trials.

“The EMPA-REG OUTCOME trial demonstrated that Jardiance reduces the risk of cardiovascular death in diabetes patients at high cardiovascular risk, and we now look forward to exploring whether Jardiance can also provide heart failure benefits,” said Professor Hans-Juergen Woerle, Global Vice President Medicine, Boehringer Ingelheim.

“One in two people with heart failure die within five years of diagnosis, so there is currently a compelling need for an effective therapy to treat those suffering from this condition,” said Dr Javed Butler, cardiologist, Stony Brook University Hospital.

About heart failure

Heart failure is when the heart cannot pump enough blood around the body. It is a debilitating condition and can be fatal. Heart failure is a prevalent disease; 26 million people around the world and 5.7 million people in the United States have chronic heart failure. Every 35 seconds a new case of heart failure is diagnosed in the United States. There is a high unmet need in the treatment of heart failure as there is significant morbidity and mortality associated with the condition. Heart failure is highly prevalent in patients with diabetes, however, approximately two-thirds of all heart failure patients do not have diabetes.

About Jardiance ®

Jardiance® (empagliflozin) is an oral, once daily, highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor approved for use in Europe, the United States and other markets around the world for the treatment of adults with type 2 diabetes.

Jardiance® works by blocking the reabsorption of glucose (blood sugar) by the kidney, leading to urinary glucose excretion and lowering blood glucose levels in people with type 2 diabetes. SGLT2 inhibition targets glucose directly and works independently of β-cell function and the insulin pathway.

Jardiance® is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).

About EMPA-REG OUTCOME ®

EMPA-REG OUTCOME® was a long-term, multicentre, randomised, double-blind, placebo-controlled trial of more than 7,000 patients from 42 countries with type 2 diabetes at high risk for cardiovascular events.

The study assessed the effect of Jardiance® (10 mg or 25 mg once daily) added to standard of care compared with placebo added to standard of care. Standard of care was comprised of glucose-lowering agents and cardiovascular drugs (including for blood pressure and cholesterol). The primary endpoint was defined as time to first occurrence of cardiovascular death, non-fatal heart attack or non-fatal stroke.

Over a median of 3.1 years, Jardiance® significantly reduced the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke by 14 percent versus placebo. Risk of cardiovascular death was reduced by 38 percent, with no significant difference in the risk of non-fatal heart attack or non-fatal stroke. Treatment with Jardiance® also resulted in a 32 percent reduced risk of all-cause mortality and a 35 percent reduced risk of hospitalisation for heart failure.

The overall safety profile of Jardiance® was consistent with that of previous trials. The incidence of diabetic ketoacidosis was at or below 0.1 percent and similar across all treatment groups.

Intended audiences

This press release is issued from Boehringer Ingelheim Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where Boehringer Ingelheim and Eli Lilly and Company do business.

###

Please click on the link below for ‘Notes to Editors’ and ‘References’:

http://www.boehringer-ingelheim.com/press-release/jardiance-empagliflozin-be-studied-treatment-people-chronic-heart-failure

Contact information

Boehringer Ingelheim GmbH
Dr. Ralph Warsinsky
Executive Director Media & PR
Email: press@boehringer-ingelheim.com
Phone: +49 178 290 8561
or
Lilly Diabetes
Greg Kueterman
Director of Communications
Email: kueterman_gregory_andrew@lilly.com
Phone: +1 (317) 277 4021

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab23.10.2017 11:15Pressemelding

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced today that the companies have expanded their existing agreement to jointly develop and commercialize investigational Alzheimer’s disease treatments. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171023005462/en/ Under the terms of the agreement Eisai has exercised its option to co-develop and co-promote aducanumab, Biogen’s investigational anti-amyloid beta (Aβ) antibody for patients with Alzheimer’s disease (“AD”). The expanded agreement leverages each company’s respective geographic strengths for commercialization and adjusts the respective share of profits from potential sales of aducanumab. Biogen will receive 55

Open Letter from Mats Granryd, Director General, GSMA23.10.2017 11:01Pressemelding

Dear Ministers, As you are no doubt aware, European citizens and businesses rely on mobile networks to socialise, do business and access information everyday in every corner of every Member State of the Union. The social and economic activity that rides over this digital infrastructure drives economic growth, shapes future innovation and fosters more inclusive societies. As you prepare to convene at tomorrow’s Ministerial Council Meeting, I must express my grave concerns on the current state of discussions on the proposed European Electronic Communication Code (the Code). Although the European Union’s vision of a ‘Gigabit Society’, and recent discussions amongst the European Heads of State, demonstrate a strong ambition to recapture the region’s digital leadership and harness the full power of digital to drive growth, jobs and competitiveness, we do not see action foc

San Francisco 49ers and IDEMIA Announce Strategic Partnership to Enhance Fan Experience23.10.2017 09:30Pressemelding

The San Francisco 49ers and IDEMIA announced a new multi-year partnership to promote and implement identity and security services from IDEMIA’S IdentoGO solution, the country’s preeminent identity-related service provider and exclusive provider of TSA Pre✓®, at Levi’s® Stadium. In addition to offering TSA Pre✓® enrollment opportunities at 49ers home games, IDEMIA will equip the stadium with biometric-based technology to assist in fan experience and security in the near future. “We’re always looking for innovative ways to enhance security at Levi’s ® Stadium and IDEMIA’S IdentoGO technology complements our efforts as we strive to provide expedited entry for pre-approved customers,” said Jim Mercurio, 49ers Vice President of stadium operations and Levi’s® Stadium general manager. “We look forward to working with IDEMIA to jointly deploy the first-ever Trusted Fan Progr

E Ink and LTS Partner to Develop Smart Patch to Improve Medical Management23.10.2017 07:00Pressemelding

E Ink Holdings, "E Ink" (8069.TW), the leading innovator of electronic ink technology and LTS Lohmann-Therapie Systeme AG, “LTS” leading in the development and manufacturing of transdermal therapeutic systems, today announced their partnership to develop a “Smart Patch” prototype. The Smart Patch prototype is a transdermal therapeutic system (TTS) that delivers medication to patients in a convenient, controlled and comfortable manner and features an E Ink display to deliver and convey relevant information about patch performance. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171023005449/en/ The “Smart Patch” prototype features an E Ink display to convey relevant information about patch performance to patients. (Photo: E Ink Holdings) According to a report conducted by the New England Healthcare Institute

MaxLinear and Corinex to Use G.hn for Open Smart Metering Solution23.10.2017 06:00Pressemelding

MaxLinear, Inc. (NYSE:MXL), a leading provider of radio frequency (RF), analog and mixed-signal integrated circuits for the connected home, wired and wireless infrastructure, and industrial and multimarket applications and Corinex, a unique supplier of broadband solutions (BPL) for smart metering and smart grid infrastructure improving grid operational efficiency, security and integration of renewable energy and EV’s today announced that they will cooperate to create a broadband utility infrastructure solution based on standard ITU-T G.hn technology to enable smart metering and other smart grid applications. The G.hn solution will address the growing interest of electricity utilities in leveraging broadband powerline networks for Smart Grid applications, while ensuring multi-vendor interoperability, openness and easy integration into a wide range of Smart Meters and Smart Grid infrastr

NTT Communications to Share Industry Views with Global Carrier Community at Capacity Europe 2017 in London23.10.2017 06:00Pressemelding

Executives from NTT Communications (NTT Com), the global data and IP services arm of Fortune Global 500 telecom leader NTT (TYO: 9432), will play a prominent speaking role at this year’s Capacity Europe conference in London – Europe’s largest annual meeting for the global carrier community. During the conference, which runs October 24-26 at the Intercontinental London 02, NTT Com executives will participate in three panels that provide expert analysis and perspective on trending industry topics including the Internet of Things (IoT), network security and the importance of innovation and leadership. NTT Com is in a unique position to address global wholesale trends and opportunities as the global carrier consistently ranks as one of the top IP network providers worldwide. “Coming together as an industry to share insights and perspective is not only beneficia

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom